| Date | Time | Source | Announcement |
|---|---|---|---|
| 14 Feb 2019 | 07:00 AM | Appointment of Nomad and Joint Broker | |
| 13 Feb 2019 | 07:00 AM | Joint venture partnership agreement with AKESOgen | |
| 06 Feb 2019 | 07:00 AM | RenalytixAI Expands Leadership Team | |
| 23 Jan 2019 | 07:00 AM | Initiates Clinical Validation Study | |
| 21 Jan 2019 | 07:00 AM | Clarification re. lock-up restrictions | |
| 02 Jan 2019 | 07:00 AM | Exercise of Option for Exclusive License | |
| 20 Dec 2018 | 05:20 PM | Director/PDMR Shareholding | |
| 20 Dec 2018 | 07:01 AM | Planned appointment of joint broker & of NOMAD | |
| 19 Dec 2018 | 06:28 PM | Director Dealing | |
| 17 Dec 2018 | 01:30 PM | Holding(s) in Company | |
| 09 Nov 2018 | 10:30 AM | Holding(s) in Company | |
| 08 Nov 2018 | 04:50 PM | Holding(s) in Company | |
| 08 Nov 2018 | 07:00 AM | Director/PDMR Shareholding | |
| 06 Nov 2018 | 07:00 AM | RENX Admission to AIM and First Day of Dealings |
Renalytix is an artificial intelligence-enabled in vitro diagnostics company which focuses on kidney disease
Renalytics share price launched at 120p in 2018.